Equities analysts expect Bausch Health Companies Inc (NYSE:BHC) to post $2.17 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Bausch Health Companies’ earnings, with the highest sales estimate coming in at $2.20 billion and the lowest estimate coming in at $2.14 billion. Bausch Health Companies posted sales of $2.13 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.9%. The business is scheduled to report its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.47 billion for the current financial year, with estimates ranging from $8.42 billion to $8.53 billion. For the next financial year, analysts expect that the company will post sales of $8.78 billion, with estimates ranging from $8.51 billion to $9.30 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last announced its earnings results on Monday, May 6th. The company reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.14. The company had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share.
In other Bausch Health Companies news, CEO Joseph C. Papa acquired 30,000 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The stock was bought at an average price of $23.67 per share, for a total transaction of $710,100.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 11.87% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FIL Ltd raised its position in Bausch Health Companies by 69.6% during the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock valued at $260,170,000 after purchasing an additional 4,327,851 shares in the last quarter. Vanguard Group Inc. purchased a new stake in Bausch Health Companies in the 3rd quarter worth approximately $223,173,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Bausch Health Companies by 0.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock worth $156,267,000 after buying an additional 75,175 shares in the last quarter. Bank of Montreal Can lifted its position in Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after buying an additional 815,311 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in Bausch Health Companies by 89.1% in the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after buying an additional 1,696,400 shares in the last quarter. 54.70% of the stock is owned by institutional investors and hedge funds.
Shares of Bausch Health Companies stock traded up $0.05 during midday trading on Monday, reaching $25.33. 129,189 shares of the company’s stock traded hands, compared to its average volume of 4,289,010. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61. The company has a market cap of $8.92 billion, a PE ratio of 6.27, a P/E/G ratio of 0.57 and a beta of 0.55. Bausch Health Companies has a 12 month low of $17.20 and a 12 month high of $28.45.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Read More: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.